UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012714
Receipt number R000014348
Scientific Title The multicenter study on heart failure treatment with intrathoracic impedance: MOMOTARO II study (MOnitoring and Management of OpTiVol Alert to Reduce heart failure hOspitalization)
Date of disclosure of the study information 2013/12/27
Last modified on 2021/01/28 13:44:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The multicenter study on heart failure treatment with intrathoracic impedance: MOMOTARO II study
(MOnitoring and Management of OpTiVol Alert to Reduce heart failure hOspitalization)

Acronym

MOMOTARO II study

Scientific Title

The multicenter study on heart failure treatment with intrathoracic impedance: MOMOTARO II study
(MOnitoring and Management of OpTiVol Alert to Reduce heart failure hOspitalization)

Scientific Title:Acronym

MOMOTARO II study

Region

Japan


Condition

Condition

Patient who has organic heart disease and requiring ICD or CRTD.
Patient received ICD or CRTD.
1) Patient with less than 40% of LVEF
2) Patient with past history of heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine what therapy is effective in patients with decreased intrathoracic impedance in OptiVol alert.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of intrathoracic impedance and BNP in OptiVol alert to that after 1 week

Key secondary outcomes

Comparison of other parameters in OptiVol alert to that after 1 week


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Furosemide 10mg/day oral

Interventions/Control_2

Nitroglycerin 10mg/day patch

Interventions/Control_3

Education of life style

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient who has organic heart disease and requiring ICD or CRTD.
Patient received ICD or CRTD.
1) Patient less than 40% of LVEF
2) Patient with past history of heart failure

Key exclusion criteria

1) Patient under 20 years old.
2) Patient with moderate or severe chronic obstructive lung disease (forced expiratory volume < 1.0 L/s).
3) Patient who is received heart transplantation or is supposed to receive heart transplantation.
4) Patient with primary pulmonary hypertension.
5) Patient with renal failure of stage IV or V. (GFR <15 mL/min/1.73 m^2)
6) Patient under one year of life expectancy.
7) Patient with pregnancy or possible pregnancy.
8) Patient in whom doctor think inadequate.
9) Patient with heart failure in enrollment.
10) Severe heart failure patients with necessity of hospitalization

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Hiroshi
Middle name
Last name Ito

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Cardiovascular Medicine

Zip code

700-8558

Address

2-5-1, Shikata-cho, Kita-ku, Okayama

TEL

086-235-7351

Email

itomd@md.okayama-u.ac.jp


Public contact

Name of contact person

1st name Akihito
Middle name
Last name Miyoshi

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Cardiovascular Medicine

Zip code

700-8558

Address

2-5-1, Shikata-cho, Kita-ku, Okayama

TEL

086-235-7351

Homepage URL

http://study.momotaro-med.com/momotaro-study/

Email

akihito344jp@yahoo.co.jp


Sponsor or person

Institute

Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Institute

Department

Personal name



Funding Source

Organization

Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Center of Innovative Clinical Medicine

Address

2-5-1, Shikata-cho, Kita-ku, Okayama city

Tel

086-235-6503

Email

mae6605@adm.okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岡山大学病院(岡山県)、倉敷中央病院(岡山県)、国立病院機構岡山医療センター(岡山県)、福山市民病院(広島県)、福山循環器病院(広島県)、香川県立中央病院(香川県)、津山中央病院(岡山県)、岩国医療センター(山口県)、済生会今治病院(愛媛県)、愛媛県立中央病院(愛媛県)、高知医療センター(高知県)、高松赤十字病院(香川県)


Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 27 Day


Related information

URL releasing protocol

https://www.jstage.jst.go.jp/article/circj/84/3/84_CJ-19-0986/_article

Publication of results

Published


Result

URL related to results and publications

https://www.jstage.jst.go.jp/article/circj/84/3/84_CJ-19-0986/_article

Number of participants that the trial has enrolled

156

Results

Our ITI algorithm could properly find slight fluid retention without apparent symptom. Early intervention, such as lifestyle modification, diuretics or nitrates, for asymptomatic HF patients diagnosed by our ITI algorithm could improve the condition of patients.

Results date posted

2021 Year 01 Month 28 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Inclusion criteria were as follows: <40% of left ventricular ejection fraction (LVEF) or a history of HF hospitalization within 1 year.

Participant flow

Patients were followed by remote monitoring. Patients come to the hospital based on a heart failure alert, and if signs of heart failure are present, they are assigned to the diuretic group, nitrate group, or lifestyle modification group, and are re-examined after one week.

Adverse events

None

Outcome measures

BNP, intrathoracic impedance

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 08 Month 28 Day

Date of IRB

2012 Year 08 Month 28 Day

Anticipated trial start date

2012 Year 09 Month 01 Day

Last follow-up date

2016 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 12 Month 27 Day

Last modified on

2021 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014348


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name